Literature DB >> 12360002

Evaluation of a staging system for infected hip arthroplasty.

Arlen D Hanssen1, Douglas R Osmon.   

Abstract

A previously reported staging system for prosthetic joint infection was evaluated in 26 consecutive patients with an infected hip arthroplasty. Six patients were treated by a definitive resection arthroplasty whereas the remaining 20 patients received delayed insertion of another hip arthroplasty. Four of the 20 patients (20%) receiving a new prosthesis had reinfection develop. The only variable in common among the patients who had reinfection was the use of a massive femoral structural allograft at reconstruction. Because of the small number of patients in this study, the power of statistical analysis did not allow definitive determination of the effect of the staging system score with respect to recurrent infection. Based on this study, recommendations can be suggested for addition and deletion of certain variables within the existing staging system. Although the concept of a staging system for treatment of an infected hip arthroplasty is promising, the number of patients required to evaluate the use of a staging system will require a multicenter collaborative study.

Entities:  

Mesh:

Year:  2002        PMID: 12360002     DOI: 10.1097/00003086-200210000-00004

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  14 in total

1.  Risk factors and a prognostic model of hip periprosthetic infection recurrence after surgical treatment using articulating and non-articulating spacers.

Authors:  Rashid Tikhilov; Svetlana Bozhkova; Alexey Denisov; Dmitry Labutin; Igor Shubnyakov; Vadim Razorenov; Vasilii Artyukh; Olga Klitsenko
Journal:  Int Orthop       Date:  2015-12-19       Impact factor: 3.075

2.  Reinfection after two-stage revision for periprosthetic infection of total knee arthroplasty.

Authors:  Bernd Kubista; Robert U Hartzler; Christina M Wood; Douglas R Osmon; Arlen D Hanssen; David G Lewallen
Journal:  Int Orthop       Date:  2011-05-07       Impact factor: 3.075

3.  Evaluation of an interdisciplinary therapy algorithm in patients with prosthetic joint infections.

Authors:  Matthias D Wimmer; Thomas M Randau; Sabine Petersdorf; Geert I Pagenstert; Markus Weißkopf; Dieter C Wirtz; Sascha Gravius
Journal:  Int Orthop       Date:  2013-07-13       Impact factor: 3.075

4.  Poor performance of microbiological sampling in the prediction of recurrent arthroplasty infection.

Authors:  Maximilian Schindler; Panayiotis Christofilopoulos; Blaise Wyssa; Wilson Belaieff; Christian Garzoni; Louis Bernard; Daniel Lew; Pierre Hoffmeyer; Ilker Uçkay
Journal:  Int Orthop       Date:  2010-04-27       Impact factor: 3.075

5.  Articulating spacers used in two-stage revision of infected hip and knee prostheses abrade with time.

Authors:  Bernd Fink; Annett Rechtenbach; Hubert Büchner; Sebastian Vogt; Michael Hahn
Journal:  Clin Orthop Relat Res       Date:  2010-07-28       Impact factor: 4.176

6.  Periprosthetic infection due to resistant staphylococci: serious problems on the horizon.

Authors:  Javad Parvizi; Khalid Azzam; Elie Ghanem; Matthew S Austin; Richard H Rothman
Journal:  Clin Orthop Relat Res       Date:  2009-05-01       Impact factor: 4.176

7.  Two-stage cementless revision of infected hip endoprostheses.

Authors:  Bernd Fink; Alexandra Grossmann; Martin Fuerst; Peter Schäfer; Lars Frommelt
Journal:  Clin Orthop Relat Res       Date:  2008-11-11       Impact factor: 4.176

Review 8.  Two-stage procedure in the treatment of late chronic hip infections--spacer implantation.

Authors:  Mohamed Sukeik; Fares S Haddad
Journal:  Int J Med Sci       Date:  2009-09-02       Impact factor: 3.738

Review 9.  Revision of late periprosthetic infections of total hip endoprostheses: pros and cons of different concepts.

Authors:  Bernd Fink
Journal:  Int J Med Sci       Date:  2009-09-04       Impact factor: 3.738

Review 10.  Classification of hip joint infections.

Authors:  Konstantinos Anagnostakos; Nora Verena Schmid; Jens Kelm; Ulrich Grün; Jochen Jung
Journal:  Int J Med Sci       Date:  2009-09-01       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.